Back to search

Article

Improving Treatment Options for Patients With Double Refractory CLL

2025-01-02

Abstract excerpt

Proliferation and survival of chronic lymphocytic leukemia (CLL) cells are heavily dependent on B-cell receptor (BCR) signaling and resistance to apoptosis. Approvals of multiple covalent Bruton's tyrosine kinas inhibitors (cBTKis) as well as the B-cell lymphoma-2 inhibitor (BCL2i) venetoclax targeting these pathways have revolutionized the treatment of CLL and small lymphocytic lymphoma (SLL). The superiority of...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
eefdebf1-576a-5232-bb36-dead2f69718d
DOI
10.20944/preprints202501.0026.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Improving Treatment Options for Patients With Double Refractory CLLDOI 10.20944/preprints202501.0026.v1
When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia.Semantic proximity
Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignanciesSemantic proximity
SOHO State of the Art Updates and Next Questions: New Targetable Pathways in Chronic Lymphocytic Leukemia.Semantic proximity
How should we sequence and combine novel therapies in CLL?Semantic proximity
Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia.Semantic proximity
Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistanceSemantic proximity
Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic StrategiesSemantic proximity
Emerging Therapies in CLL in the Era of Precision MedicineSemantic proximity
Therapeutics targeting Bcl-2 in hematological malignanciesSemantic proximity
The potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaSemantic proximity
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical developmentSemantic proximity
SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Semantic proximity
Select a neighboring publication to make it the new centre.